It is, thus, likely that the CpdA preferentially induces GR-mediated transrepression, but not transactivation, in bladder cancer cells, suggesting that treatment with the CpdA in vivo may be associated with fewer glucocorticoid-related adverse effects. This evidence concerns the gene NR3C1 and urinary bladder carcinoma.